Loading…
← CockpitCompetitor Analysis › AARTIPHARM.NS Aarti Pharmalabs LimitedOpen in the cockpit ↗

Aarti Pharmalabs LimitedAARTIPHARM.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major
Momentum leader 92
Mkt cap
$984M
US dollars, full cap
Free float
56%
of shares outstanding
$/day
$7.27M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-3.7 pp
WACC 12.9%
Hurdle
n/a
no reverse DCF
Next earnings
84 days
10 Feb 2027
Close · INR₹1,013
1D-0.2%
1W+9.7%
1M+21.8%
3M+15.9%
6M+43.6%
YTD+34.7%
1Y+33.4%
ATR %4.4%
Beta1.21
52w lowhigh3.2% off high

What Aarti Pharmalabs does

Employees: 4,218

Aarti Pharmalabs at a glance

Size Aarti Pharmalabs (AARTIPHARM.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $984M, the 608th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,013 on 18 Nov 2026.

Performance Over six months the shares gained 43.6%, against -17.5% for the median peer and +3.8% for the India market (cap-weighted) — 2nd highest of 21 in its peer set.

Growth Revenue grew 13.4% over the last twelve months (peer median +5.7%); the operating margin is 17.7% (peer median 12.5%).

Valuation It trades at 4.7× enterprise value to sales against a peer median of 3.3× (6th most expensive of 19).

Capital Return on invested capital runs 3.7 points below its cost of capital (12.9% WACC).

Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026AARTIPHARM.NS 145Peer median 86
Six months, rebased to 100: Aarti Pharmalabs against the median of its 20 peers (local-currency closes).

Aarti Pharmalabs financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹21.6B₹17.9B₹20.9B₹18.2B₹19.4B
Revenue growth—-14%+15%-6%—
Gross profit₹8.59B₹4.93B₹5.94B₹3.93B₹4.07B
EBITDA₹5.00B₹3.81B₹4.42B₹3.55B₹3.36B
Net income₹2.57B₹1.75B₹2.72B₹2.17B₹1.93B
Free cash flown/a-₹1.84B-₹893M₹466M₹1.28B
Capital expendituren/a₹4.48B₹4.44B₹1.99B₹1.20B
Total debt₹8.97B₹7.54B₹4.13B₹2.85B₹2.15B

Quarterly statements and history in the cockpit →

Aarti Pharmalabs competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%+20%688382600129SPTXPGHL600557456568871060511668809168875930029448873007022005300497603538688513002437AARTIPHARM.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Aarti Pharmalabs is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%+100%0×25×50×75×688382600129PGHL6005574565688091300294300702300497002437AARTIPHARM.NSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Aarti Pharmalabs is the large dot.

Aarti Pharmalabs competitors and peer comparison

How Aarti Pharmalabs compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Aarti Pharmalabs against its 20 peers (data as of 18 Nov 2026)
MeasureAARTIPHARM.NSPeer medianRank in peer set
1-month return+21.8%-9.0%2nd highest of 21
6-month return+43.6%-17.5%2nd highest of 21
Distance from 52-week high-3.2%-39.2%highest of 21
Revenue growth (TTM)+13.4%+5.7%7th highest of 19
Operating margin17.7%12.5%4th highest of 19
EV / Sales4.7×3.3×6th most expensive of 19
ROIC minus cost of capital-3.7 pp+0.1 pp3rd lowest of 19
EV / EBITDA20.1×11.1×2nd most expensive of 6
Net debt / EBITDA1.8×2.1×2nd least indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Aarti Pharmalabs AARTIPHARM.NSIndia$984M+44%+13%18%4.7×n/an/a
InventisBio 688382.SSChina$982M-47%-61%-563%75.0×6.5%-60.6%
Chongqing Taiji Industry (Group) 600129.SSChina$982M-20%-4%2%1.3×n/an/a
Seaport Therapeutics SPTXUnited States$980M+16%n/an/an/an/an/a
Procter & Gamble Health PGHL.NSIndia$979M+3%+13%31%6.3×5.6%+9.3%
Jiangsu Kanion Pharmaceutical 600557.SSChina$989M-9%+8%7%1.4×2.3%+1.8%
Nxera Pharma 4565.TJapan$974M+46%+24%14%5.4×17.7%+27.3%
Shanghai InnoStar Bio-tech 688710.SSChina$1,000M+17%+24%6%5.2×12.7%+19.4%
Aurisco Pharmaceutical 605116.SSChina$1.00B-23%+3%25%4.2×-2.0%+18.7%
Shanghai Yizhong Pharmaceutical 688091.SSChina$1.00B-49%+32%14%19.3×n/an/a
BeBetter Med 688759.SSChina$960M-58%n/an/an/an/an/a
China Resources Boya Bio-pharmaceutical 300294.SZChina$959M-21%-27%-19%2.5×n/an/a
SAWAI 4887.TJapan$1.01B-18%+2%9%1.3×n/an/a
Renhe Pharmacy 000650.SZChina$1.01B-12%-7%14%0.9×-10.7%-7.0%
Zhejiang Tianyu Pharmaceutical 300702.SZChina$1.02B+1%+27%4%2.3×4.3%+3.5%
SSY 2005.HKHong Kong$948M+8%-4%12%2.2×2.3%-0.5%
Strides Pharma Science STAR.NSIndia$946M-17%+11%14%2.0×17.6%+7.8%
Jiangxi Fushine Pharmaceutical 300497.SZChina$1.02B-23%+103%24%4.0×7.5%-4.5%
Ningbo Menovo Pharmaceutical 603538.SSChina$945M-48%+19%9%3.8×11.6%+4.9%
Chengdu Easton Biopharmaceuticals 688513.SSChina$1.03B-33%-2%13%4.2×4.4%+7.7%
Harbin Gloria Pharmaceuticals 002437.SZChina$941M-9%-16%13%2.8×7.7%-6.9%

Questions

Which companies are Aarti Pharmalabs's closest peers?
The cockpit's peer set: InventisBio (688382.SS), Chongqing Taiji Industry (Group) (600129.SS), Seaport Therapeutics (SPTX), Procter & Gamble Health (PGHL.NS), Jiangsu Kanion Pharmaceutical (600557.SS), Nxera Pharma (4565.T), Shanghai InnoStar Bio-tech (688710.SS), Aurisco Pharmaceutical (605116.SS).
Is Aarti Pharmalabs expensive compared with its peers?
On ev / sales it trades at 4.7× against a peer median of 3.3×, 6th most expensive of 19 in its peer set.
How has Aarti Pharmalabs stock performed?
Over six months to 18 Nov 2026 the shares returned +43.6% against -17.5% for the median peer; over one year +33.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.